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ive intervention to meet the needs of these patient populations and their 
caregivers. 
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Background: The assessment of performance status according to the 
classical Karnofsky or ECOG scales has been shown to be an effec-
tive predictor of outcome in several oncological studies. However, its 
application to patients over 70 years of age has limited utility and may 
uderrepresent the degree of functional impairment). Comorbidity and 
functional status according to ECOG, ADL and IADL have shown 
to be independent in older cancer patients. However, some degree of 
correlation between comorbidity and IADL has been reported before. 
Geriatric assessment is a time-consuming task sometimes difﬁcult to 
perform by oncologists out of clinical trials. The experience of a single 
institution about elderly lung cancer patients in an out patient setting 
will be presented. 
Methods: For geriatric assessment the following characteristics were 
considered:
• Comorbidity by means of Charlson and Kaplan Feinstein scores
• Activities of daily living (ADL)
• Instrumental activities of daily living (IADL)
• Nutritional status by means of proteins/albumin levels and/or BMI
• Cognitive mental status is examined with the Mini-Mental state
• Expression of depression with the Geriatric Depression Screening
• Scale (GDSS)
• Family/Institutional support.
Results: By Febrery/2007 seventy elderly lung cancer patients (pts) 
have been analyzed in our institution. The main descriptive character-
istics were: median age 76 years (70-84 ); stage disease, II in 5.7 %, III 
in 45.8 % and IV in 57.1 % of the pts; distribution of performance sta-
tus (ECOG) was: PS 0/10 %, PS 1/50 % and PS 2/40 %; sex: M (84 %) 
and F (16 %). Serum albumin level was lesser than 3.5 g/dl in 28 % of 
the patients. Comorbidity according to Charlson and Kaplan scales was 
presented in 74.2 % and 82 % of pts respectively. Ability in 51-99 % of 
ADL and IADL was able in 25 % and 39.7% of pts and was < 50 % in 
8.8 % and 22.1 % of pts. Mini-Mental state was applied to 33 patients, 
40 % of them obtained a punctuation < 25. Treatment administered was: 
surgery in 1 pt, radiotherapy alone in 2 pts, chemo-radiotherapy in 11 
pts, chemotherapy alone in 55 pts and tyrosine-kinase inhibitor in 1 pt.
Conclusions: The analysis is ongoing but the heterogeneity of the 
pts in these preliminary results suggests the importance to carry out a 
detailed evaluation of elderly lung cancer patients for detecting several 
situations not detectable by means of a conventional examination. A 
more completed analysis of comorbid, clinical, nutritional and social 
conditions will be presented at the meeting. Correlation between dif-
ferent factors and the inﬂuence of them on the outcome of the elderly 
patients will be examined. 
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Background: As there are few published data on the treatment costs 
of lung cancer, health economic data is valuable for physicians making 
treatment decisions as well as health authorities to develop reimburse-
ment and treatment guidelines. This study is aimed to collect data on 
direct health care costs related to treatment of advanced stage IIIB/IV 
non-small cell lung cancer (NSCLC) in Finland. 
Methods: The costs analysis was based on data reﬂecting consumption 
of the health care resources and medication in Helsinki University Hos-
pital and Turku University Hospital. The data was collected retrospec-
tively from the medical records of 65 advanced stage IIIB/IV NSCLC 
patients who participated in a phase IV erlotinib clinical trial (TRUST). 
In this abstract, interim data on 42 patients is presented. The resource 
utilization data for all treatments was collected from the day patients 
ﬁrst visited the health care unit with diagnosed advanced stage IIIB/IV 
NSCLC until discontinuation of therapy or patient death. The following 
cost categories were included in the analysis: total direct health care 
costs, chemotherapy costs (including drug and administration costs) 
and costs associated with adverse reactions. The 2001 Finnish Guide-
lines for Health Care Unit Costs converted to 2005 cost levels were 
used to value the costs of the health care resources. A published price 
list of pharmaceuticals (SLD Price 2006) was used to value the prices 
of chemotherapies and other medications.
Results: In the interim analysis, the mean total costs per patient in 
different treatment lines were; Line 1 (n=37): 10 652 €; Line 2 (n=35): 
10 054 €; Line 3 (n=26): 10 143 €; Line 4 (n=6): 12 790 €. The mean 
total costs per patient in different chemotherapies were; combination 
treatments (n=34): 11 359 €; docetaxel (n=7): 15 933 €; vinorelbine 
(n=5): 13 819 €; gemcitabine (n=2): 6 184 €; pemetrexed (n=8): 12 
618 €; erlotinib (n=42): 8 407 €; other (n=6): 8 871 €. The mean costs 
of adverse reactions per patient (out-patient visits or hospital days) 
were; erlotinib (n=14): 130 €; other chemotherapy (n=13): 1 796 €.
Conclusions: The total average cost per advanced stages IIIB/IV 
NSCLC patient was 30 900 €. The major cost drivers in all treatment 
lines were chemotherapy (including drug and administration costs) and 
hospitalization costs. In treatment of advanced stage IIIB/IV NSCLC, 
treatment with erlotinib incurred the lowest treatment costs (including 
drug and administration costs) and AE related costs. Final results of the 
analysis will be presented in the conference.
